The present study included 30 patients presenting with chronic hepatitis B who were treated with analogs of nucleot(s)ides. Entecavir was given to 11 patients at a dose of 0.5 mg/24 hours. The remaining 19 patients were treated with other nucleotide analogs. The duration of the treatment varied from 4 to 208 weeks (mean 107 weeks). The response to the antiviral treatment was documented in 25 (83.33%) cases. 45.46% of the patients treated with entecavir and in 21.05% of those given other nucleotide analogs respectively experienced a reduction of the HBsAg levels by 1 log or more compared with the respective initial values. Among the 20 patients who completed the course of therapy only three failed to respond to the treatment. Replication of NBV DNA resumed in 16 patients after the termination of therapy. The stable virological response (reduction of the HBV DNA level to below the sensitivity of the method for its measurement within 24 weeks or more after the end of therapy and HBsAg seroconversion) took place in a single patient with chronic hepatitis B. It is concluded that the present study confirmed the beneficial safety profile of nucleotide analogs applied for the treatment of the patients presenting with chronic hepatitis B. At present, these agents are prescribed to reduce replication of the pathogen to the unmeasurable level for a maximally long period rather than its complete eradication; such an approach allows the frequency of unfavourable outcomes of the disease to be reduced.